Cargando…
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
The occurrence of chronic myeloid leukemia (CML), or other myeloproliferative diseases, after the development of idiopathic thrombocytopenic purpura (ITP) is very rare in the current medical literature. Considering the advances in ITP management, and the wide use of new drugs for ITP and CML, we rep...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708281/ https://www.ncbi.nlm.nih.gov/pubmed/34946271 http://dx.doi.org/10.3390/medicina57121326 |
_version_ | 1784622644959641600 |
---|---|
author | Autore, Francesco Sora’, Federica Chiusolo, Patrizia Minnella, Gessica Colangelo, Maria Rossi, Elena Sica, Simona |
author_facet | Autore, Francesco Sora’, Federica Chiusolo, Patrizia Minnella, Gessica Colangelo, Maria Rossi, Elena Sica, Simona |
author_sort | Autore, Francesco |
collection | PubMed |
description | The occurrence of chronic myeloid leukemia (CML), or other myeloproliferative diseases, after the development of idiopathic thrombocytopenic purpura (ITP) is very rare in the current medical literature. Considering the advances in ITP management, and the wide use of new drugs for ITP and CML, we report an unusual case with this association. Our case report focused on a 64-year-old man with long-standing ITP treated with eltrombopag, who developed hyperleukocytosis during follow-up; after specific laboratory exams, it was diagnosed as CML and he began treatment with imatinib. The treatment with eltrombopag was balanced with imatinib to stabilize his platelet count. Data on bcr-abl and JAK2 transcripts were collected and revealed an optimal response with the achievement of negativization of both molecular signatures. We could demonstrate that treatment with imatinib and eltrombopag was well tolerated and allowed complete molecular remission of CML to be achieved, as well as of ITP. |
format | Online Article Text |
id | pubmed-8708281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87082812021-12-25 Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag Autore, Francesco Sora’, Federica Chiusolo, Patrizia Minnella, Gessica Colangelo, Maria Rossi, Elena Sica, Simona Medicina (Kaunas) Case Report The occurrence of chronic myeloid leukemia (CML), or other myeloproliferative diseases, after the development of idiopathic thrombocytopenic purpura (ITP) is very rare in the current medical literature. Considering the advances in ITP management, and the wide use of new drugs for ITP and CML, we report an unusual case with this association. Our case report focused on a 64-year-old man with long-standing ITP treated with eltrombopag, who developed hyperleukocytosis during follow-up; after specific laboratory exams, it was diagnosed as CML and he began treatment with imatinib. The treatment with eltrombopag was balanced with imatinib to stabilize his platelet count. Data on bcr-abl and JAK2 transcripts were collected and revealed an optimal response with the achievement of negativization of both molecular signatures. We could demonstrate that treatment with imatinib and eltrombopag was well tolerated and allowed complete molecular remission of CML to be achieved, as well as of ITP. MDPI 2021-12-03 /pmc/articles/PMC8708281/ /pubmed/34946271 http://dx.doi.org/10.3390/medicina57121326 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Autore, Francesco Sora’, Federica Chiusolo, Patrizia Minnella, Gessica Colangelo, Maria Rossi, Elena Sica, Simona Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag |
title | Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag |
title_full | Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag |
title_fullStr | Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag |
title_full_unstemmed | Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag |
title_short | Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag |
title_sort | chronic myeloid leukemia in a patient with previous idiopathic thrombocytopenic purpura: how to manage imatinib together with eltrombopag |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708281/ https://www.ncbi.nlm.nih.gov/pubmed/34946271 http://dx.doi.org/10.3390/medicina57121326 |
work_keys_str_mv | AT autorefrancesco chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag AT sorafederica chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag AT chiusolopatrizia chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag AT minnellagessica chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag AT colangelomaria chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag AT rossielena chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag AT sicasimona chronicmyeloidleukemiainapatientwithpreviousidiopathicthrombocytopenicpurpurahowtomanageimatinibtogetherwitheltrombopag |